Mechanisms of vein graft adaptation to the arterial circulation - Insights into the neointimal algorithm and management strategies

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1501-1512

  Muto, Akihito ^a,b   Model, Lynn ^a,b   Ziegler, Kenneth ^a,b   Eghbalieh, Sammy D D ^a,c   Dardik, Alan ^a,b,c  

^a Interdepartmental Program in Vascular Biology and Therapeutics   (United States)

^b Section of Vascular Surgery   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptation; Eph B4; Nogo B; Vein grafts; Veins

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ACETYLSALICYLIC ACID; ACTIVIN A; ADENOVIRUS VECTOR; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; CILOSTAZOL; EPHRIN B2; EPHRIN B4; FLAVONOID; IMATINIB; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE PROTEIN; NITRIC OXIDE; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; PROTEIN NOGO; RAPAMYCIN; RECOMBINANT VASCULOTROPIN; SIMVASTATIN; SONIC HEDGEHOG PROTEIN; SURAMIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VIRUS PROTEIN;

ADAPTATION; ANGIOGENESIS; ARTERIAL CIRCULATION; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTERY RECONSTRUCTION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; GRAFT FAILURE; HUMAN; LEUKOCYTE MIGRATION; LIMB ISCHEMIA; MOLECULAR MECHANICS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VEIN GRAFT; VEIN THROMBOSIS; VEIN TRANSPLANTATION; VEIN WALL; WALL STRESS;

ADAPTATION, PHYSIOLOGICAL; ARTERIES; BLOOD CIRCULATION; HUMANS; NEOINTIMA; VASCULAR GRAFTING; VEINS;

EID: 77955071887     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0495     Document Type: Review

References (123)

1. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafuoro-ethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3: 104-114.
2. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: Angi-ographic follow-up of 5,065 grafts related to survival and reopera-tion in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-626.
3. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742-751.
4. Alexander JH, Hafey G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, et al; PREVENT IV Investigators. Effcacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery. PREVENT IV: A randomized controlled trial. JAMA 2005; 294: 2446-2454.
5. You LR, Lin FJ, Lee CT, DeMayo FJ, Tsai MJ, Tsai SY. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature 2005; 435: 98-104.
6. Adams RH. Molecular control of arterial-venous blood vessel identity. J Anat 2003; 202: 105-112.
7. Swift MR, Weinstein BM. Arterial-venous specifcation during development. Circ Res 2009; 104: 576-588.
8. Foo SS, Turner CJ, Adams S, Compagni A, Aubyn D, Kogata N, et al. Ephrin-B2 controls cell motility and adhesion during bloodvessel-wall assembly. Cell 2006; 124: 161-173.
9. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 2002; 3: 475-486.
10. Kudo FA, Muto A, Maloney SP, Pimiento JM, Bergaya S, Fitzgerald TN, et al. Venous identity is lost but arterial identity is not gained during vein graft adaptation. Arterioscler Thromb Vasc Biol 2007; 27: 1562-1571.
11. Vesti BR, Primozich J, Bergelin RO, Strandness E Jr. Follow-up of valves in saphenous vein bypass grafts with duplex ultrasonog-raphy. J Vasc Surg 2001; 33: 369-374.
12. Singh RN. Flow disturbance due to venous valves: A cause of graft failure. Cathet Cardiovasc Diagn 1986; 12: 35-38.
13. Lajos TZ, Robicsek F, Thubrikar M, Urschel H. Improving patency of coronary conduits "valveless" veins and/or arterial grafts. J Card Surg 2007; 22: 170-177.
14. Mitra AK, Gangahar DM, Agrawal DK. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 2006; 84: 115-124.
15. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
16. Furchgott RF. Endothelium-derived relaxing factor: Discovery, early studies, and identifcation as nitric oxide. Biosci Rep 1999; 19: 235-251.
17. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prosta-cyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
18. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-1058.
19. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin: Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arte-rioscler Thromb 1991; 11: 254-260.
20. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibi-tor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991; 266: 9419-9427.
21. Snow AD, Bolender RP, Wight TN, Clowes AW. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990; 137: 313-330.
22. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265: 625-626.
23. Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries: Interaction of heparin with basic fbroblast growth factor. J Clin Invest 1992; 90: 2044-2049.
24. McGeachie JK, Meagher S, Prendergast FJ. Vein-to-artery grafts: The long-term development of neo-intimal hyperplasia and its relationship to vasa vasorum and sympathetic innervation. Aust NZ J Surg 1989; 59: 59-65.
25. de Graaf R, Tintu A, Stassen F, Kloppenburg G, Bruggeman C, Rouwet E. N-acetylcysteine prevents neointima formation in experimental venous bypass grafts. Br J Surg 2009; 96: 941-950.
26. Conte MS. Technical factors in lower-extremity vein bypass surgery: How can we improve outcomes? Semin Vasc Surg 2009; 22: 227-233.
27. Liu SQ, Ruan YY, Tang D, Li YC, Goldman J, Zhong L. A possible role of initial cell death due to mechanical stretch in the regulation of subsequent cell proliferation in experimental vein grafts. Biomech Model Mechanobiol 2002; 1: 17-27.
28. Angelini GD, Lloyd C, Bush R, Johnson J, Newby AC. An external, oversized, porous polyester stent reduces vein graft neointima formation, cholesterol concentration, and vascular cell adhesion molecule 1 expression in cholesterol-fed pigs. J Thorac Cardio-vasc Surg 2002; 124: 950-956.
29. Dashwood MR, Angelini GD, Wan S, Yim A, Mehta D, Izzat MB, et al. Does external stenting reduce procine vein-graft occlusion via an action on vascular nerves? J Card Surg 2002; 17: 556-560.
30. Jeremy JY, Bulbulia R, Johnson JL, Gadsdon P, Vijayan V, Shukla N, et al. A bioabsorbable (polyglactin), nonrestrictive, external sheath inhibits porcine saphenous vein graft thickening. J Thorac Cardiovasc Surg 2004; 127: 1766-1772.
31. Vijayan V, Smith FC, Angelini GD, Bulbulia RA, Jeremy JY. External supports and the prevention of neointima formation in vein grafts. Eur J Vasc Endovasc Surg 2002; 24: 13-22.
32. Cheng J, Du J. Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor. Arterioscler Thromb Vasc Biol 2007; 27: 1744-1751.
33. Kozai T, Eto M, Yang Z, Shimokawa H, Lüscher TF. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res 2005; 68: 475-482.
34. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for fow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-1319.
35. Gratton JP, Bernatchez P, Sessa WC. Caveolae and caveolins in the cardiovascular system. Circ Res 2004; 94: 1408-1417.
36. Ohta S, Komori K, Yonemitsu Y, Onohara T, Matsumoto T, Sugimachi K. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: A limited biological effect as a result of the loss of medial smooth muscle cells. Surgery 2002; 131: 644-653.
37. Hattori K, Yamanouchi D, Banno H, Kobayashi M, Yamamoto K, Kajikuri J, et al. Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. J Vasc Surg 2007; 46: 116-123.
38. Wan S, Shukla N, Angelini GD, Yim AP, Johnson JL, Jeremy JY. Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: A comparison with aspirin and morpholinosydnonimine (SIN-1). J Thorac Cardiovasc Surg 2007; 134: 1033-1039.
39. Shukla N, Angelini GD, Ascione R, Talpahewa S, Capoun R, Jeremy JY. Nitric oxide donating aspirins: Novel drugs for the treatment of saphenous vein graft failure. Ann Thorac Surg 2003; 75: 1437-1442.
40. Lee MS, David EM, Makkar RR, Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: The intertwining roles of platelets, leucocytes, and the coagulation-fbrinolysis system. J Pathol 2004; 203: 861-870.
41. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg 1994; 81: 1254-1269.
42. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postan-gioplasty restenosis: Platelet activation and the coagulation-fbri-nolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-392.
43. Yamamoto K, Onoda K, Sawada Y, Fujinaga K, Imanaka-Yoshida K, Yoshida T, et al. Locally applied cilostazol suppresses neointi-mal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg 2007; 13: 322-330.
44. Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-157.
45. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leucocyte recruitment. J Clin Invest 1997; 100: S97-S103.
46. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 2006; 26: 2063-2069.
47. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: Intercellular adhesion molecule-2. J Clin Invest 1994; 94: 1243-1251.
48. Zou Y, Hu Y, Mayr M, Dietrich H, Wick G, Xu Q. Reduced neo-intima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-defcient mice. Circ Res 2000; 86: 434-440.
49. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leucocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
50. Wolff RA, Tomas JJ, Hullett DA, Stark VE, van Rooijen N, Hoch JR. Macrophage depletion reduces monocyte chemotactic protein-1 and transforming growth factor-beta1 in healing rat vein grafts. J Vasc Surg 2004; 39: 878-888.
51. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol 2004; 24: 470-476.
52. Fogelstrand P, Osterberg K, Mattsson E. Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue. Cardiovasc Res 2005; 67: 326-332.
53. Gotoh R, Suzuki J, Kosuge H, Kakuta T, Sakamoto S, Yoshida M, et al. E-selectin blockade decreases adventitial infammation and attenuates intimal hyperplasia in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 2004; 24: 2063-2068.
54. Siow RC, Churchman AT. Adventitial growth factor signalling and vascular remodelling: Potential of perivascular gene transfer from the outside-in. Cardiovasc Res 2007; 75: 659-668.
55. Wainwright CL, Miller AM, Wadsworth RM. Infammation as a key event in the development of neointima following vascular balloon injury. Clin Exp Pharmacol Physiol 2001; 28: 891-895.
56. Jiang Z, Berceli SA, Pfahnl CL, Wu L, Goldman D, Tao M, et al. Wall shear modulation of cytokines in early vein grafts. J Vasc Surg 2004; 40: 345-350.
57. Puhakka HL, Turunen P, Gruchala M, Bursill C, Heikura T, Vajanto I, et al. Effects of vaccinia virus anti-infammatory protein 35K and TIMP-1 gene transfers on vein graft stenosis in rabbits. In Vivo 2005; 19: 515-521.
58. Cayci C, Wahlquist TC, Seckin SI, Ozcan V, Tekinay AB, Martens TP, et al. Naringenin inhibits neointimal hyperplasia following arterial reconstruction with interpositional vein graft. Ann Plast Surg 2010; 64: 105-113.
59. de Graaf R, Kloppenburg G, Tintu A, Rouwet E, Kitslaar P, van Hooff J, et al. The new immunosuppressive agent FK778 attenuates neointima formation in an experimental venous bypass graft model. Vascul Pharmacol 2009; 50: 83-88.
60. Adkins JR, Castresana MR, Wang Z, Newman WH. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells. Am Surg 2004; 70: 384-387; discussion 387-388.
61. Schachner T, Oberhuber A, Zou Y, Tzankov A, Ott H, Laufer G, et al. Rapamycin treatment is associated with an increased apopto-sis rate in experimental vein grafts. Eur J Cardiothorac Surg 2005; 27: 302-306.
62. Schachner T, Zou Y, Oberhuber A, Tzankov A, Mairinger T, Laufer G, et al. Local application of rapamycin inhibits neointimal hyper-plasia in experimental vein grafts. Ann Thorac Surg 2004; 77: 1580-1585.
63. Peppel K, Zhang L, Orman ES, Hagen PO, Amalftano A, Brian L, et al. Activation of vascular smooth muscle cells by TNF and PDGF: Overlapping and complementary signal transduction mechanisms. Cardiovasc Res 2005; 65: 674-682.
64. Zhang L, Peppel K, Brian L, Chien L, Freedman NJ. Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. Arterioscler Thromb Vasc Biol 2004; 24: 2277-2283.
65. Zhang L, Sivashanmugam P, Wu JH, Brian L, Exum ST, Freedman NJ, et al. Tumor necrosis factor receptor-2 signaling attenuates vein graft neointima formation by promoting endothe-lial recovery. Arterioscler Thromb Vasc Biol 2008; 28: 284-289.
66. Bretschneider E, Braun M, Fischer A, Wittpoth M, Glusa E, Schrör K. Factor Xa acts as a PDGF-independent mitogen in human vascular smooth muscle cells. Thromb Haemost 2000; 84: 499-505.
67. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-1022.
68. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-2315.
69. Huynh TT, Davies MG, Thompson MA, Ezekowitz MD, Hagen P, Annex BH. Local treatment with recombinant tissue factor pathway inhibitor reduces the development of intimal hyperplasia in experimental vein grafts. J Vasc Surg 2001; 33: 400-407.
70. Torsney E, Mayr U, Zou Y, Thompson WD, Hu Y, Xu Q. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res 2004; 94: 1466-1473.
71. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, et al. Long-term graft patency (3 years) after coronary artery surgery: Effects of aspirin: Results of a VA Cooperative study. Circulation 1994; 89: 1138-1143.
72. Kim AY, Walinsky PL, Kolodgie FD, Bian C, Sperry JL, Deming CB, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: Implications for vein graft failure. Circ Res 2002; 90: 205-212.
73. Amabile PG, Wang DS, Kao EY, Lee J, Elkins CJ, Yuksel E, et al. Directed migration of smooth muscle cells to engineer plaque-resistant vein grafts. J Endovasc Ther 2005; 12: 667-675.
74. Luo Z, Asahara T, Tsurumi Y, Isner JM, Symes JF. Reduction of vein graft intimal hyperplasia and preservation of endothelium-dependent relaxation by topical vascular endothelial growth factor. J Vasc Surg 1998; 27: 167-173.
75. Lahtinen M, Blomberg P, Baliulis G, Carlsson F, Khamis H, Zemgulis V. In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts. Eur J Cardiothorac Surg 2007; 31: 383-390.
76. Mayr U, Zou Y, Zhang Z, Dietrich H, Hu Y, Xu Q. Accelerated arteriosclerosis of vein grafts in inducible NO synthase (-/-) mice is related to decreased endothelial progenitor cell repair. Circ Res 2006; 98: 412-420.
77. Heydarkhan-Hagvall S, Helenius G, Johansson BR, Li JY, Mattsson E, Risberg B. Co-culture of endothelial cells and smooth muscle cells affects gene expression of angiogenic factors. J Cell Biochem 2003; 89: 1250-1259.
78. Jia G, Mitra AK, Gangahar DM, Agrawal DK. Regulation of cell cycle entry by PTEN in smooth muscle cell proliferation of human coronary artery bypass conduits. J Cell Mol Med 2009; 13: 547-554.
79. Mitra AK, Jia G, Gangahar DM, Agrawal DK. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits. J Cell Mol Med 2009; 13: 177-187.
80. Wolff RA, Malinowski RL, Heaton NS, Hullett DA, Hoch JR. Transforming growth factor-beta1 antisense treatment of rat vein grafts reduces the accumulation of collagen and increases the accumulation of h-caldesmon. J Vasc Surg 2006; 43: 1028-1036.
81. Ranjzad P, Salem HK, Kingston PA. Adenovirus-mediated gene transfer of fbromodulin inhibits neointimal hyperplasia in an organ culture model of human saphenous vein graft disease. Gene Ther 2009; 16: 1154-1162.
82. Kloppenburg GT, Grauls GE, Bruggeman CA, Stassen FR. Adeno-viral activin A expression prevents vein graft intimal hyperplasia in a rat model. Interact Cardiovasc Thorac Surg 2009; 8: 31-34.
83. Yamashita A, Hanna AK, Hirata S, Dardik A, Sumpio BE. Anti-sense basic fbroblast growth factor alters the time course of mito-gen-activated protein kinase in arterialized vein graft remodeling. J Vasc Surg 2003; 37: 866-873.
84. Huang B, Dreyer T, Heidt M, Yu JC, Philipp M, Hehrlein FW, et al. Insulin and local growth factor PDGF induce intimal hyper-plasia in bypass graft culture models of saphenous vein and internal mammary artery. Eur J Cardiothorac Surg 2002; 21: 1002-1008.
85. Hu Y, Zou Y, Dietrich H, Wick G, Xu Q. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 1999; 100: 861-868.
86. Kimura S, Egashira K, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation 2008; 118(Suppl): S65-S70.
87. Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K. Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 2006; 44: 633-641.
88. Pintucci G, Saunders PC, Gulkarov I, Sharony R, Kadian-Dodov DL, Bohmann K, et al. Anti-proliferative and anti-infammatory effects of topical MAPK inhibition in arterialized vein grafts. FASEB J 2006; 20: 398-400.
89. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, Galloway AC, et al. Matrix metalloproteinase expression in vein grafts: Role of infammatory mediators and extracellular signal-regulated kinases-1 and -2. Am J Physiol Heart Circ Physiol 2006; 290: H1651-H1659.
90. Hata JA, Petrofski JA, Schroder JN, Williams ML, Timberlake SH, Pippen A, et al. Modulation of phosphatidylinositol 3-kinase signaling reduces intimal hyperplasia in aortocoronary saphenous vein grafts. J Thorac Cardiovasc Surg 2005; 129: 1405-1413.
91. Wan S, George SJ, Nicklin SA, Yim AP, Baker AH. Overexpres-sion of p53 increases lumen size and blocks neointima formation in porcine interposition vein grafts. Mol Ther 2004; 9: 689-698.
92. Mayr U, Mayr M, Li C, Wernig F, Dietrich H, Hu Y, et al. Loss of p53 accelerates neointimal lesions of vein bypass grafts in mice. Circ Res 2002; 90: 197-204.
93. Frischknecht K, Greutert H, Weisshaupt C, Kaspar M, Yang Z, Luscher TF, et al. Different vascular smooth muscle cell apopto-sis in the human internal mammary artery and the saphenous vein: Implications for bypass graft disease. J Vasc Res 2006; 43: 338-346.
94. Yamanouchi D, Banno H, Nakayama M, Sugimoto M, Fujita H, Kobayashi M, et al. Hydrophilic statin suppresses vein graft inti-mal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 2005; 42: 757-764.
95. Ming XF, Viswambharan H, Barandier C, Ruffeux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxidase synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-8477.
96. Turner NA, O'Regan DJ, Ball SG, Porter KE. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J 2005; 19: 804-806.
97. Fujita H, Banno H, Yamanouchi D, Kobayashi M, Yamamoto K, Komori K. Pitavastatin inhibits intimal hyperplasia in rabbit vein graft. J Surg Res 2008; 148: 238-243.
98. Lamfers ML, Aalders MC, Grimbergen JM, de Vries MR, Kockx MM, van Hinsbergh VW, et al. Adenoviral delivery of a constitu-tively active retinoblastoma mutant inhibits neointima formation in a human explant model for vein graft disease. Vascul Pharmacol 2002; 39: 293-301.
99. Mann MJ, Conte MS. Transcription factor decoys for the prevention of vein bypass graft failure (Review). Am J Cardiovasc Drugs 2003; 3: 79-85.
100. Jia G, Cheng G, Gangahar DM, Agrawal DK. Involvement of connexin 43 in angiotensin II-induced migration and proliferation of saphenous vein smooth muscle cells via the MAPK-AP-1 signaling pathway. J Mol Cell Cardiol 2008; 44: 882-890.
101. Jia G, Mitra AK, Cheng G, Gangahar DM, Agrawal DK. Angio-tensin II and IGF-1 regulate connexin43 expression via ERK and p38 signaling pathways in vascular smooth muscle cells of coronary artery bypass conduits. J Surg Res 2007; 142: 137-142.
102. Kusch B, Waldhans S, Sattler A, Wagner A, Hecker M, Moosdorf R, et al. Inhibition of carotis venous bypass graft disease by intra-operative nucleic acid-based therapy in rabbits. Thorac Cardio-vasc Surg 2006; 54: 388-392.
103. Wan S, Yim AP, Johnson JL, Shukla N, Angelini GD, Smith FC, et al. The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Car-diovasc Surg 2004; 127: 1317-1322.
104. Ni J, Waldman A, Khachigian LM. c-Jun regulates shear- and in-jury-inducible Egr-1 expression, vein graft stenosis after autolo-gous end-to-side transplantation in rabbits, and intimal hyperplasia in human saphenous veins. J Biol Chem 2010; 285: 4038-4048.
105. Miyake T, Aoki M, Shiraya S, Tanemoto K, Ogihara T, Kaneda Y, et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleo-tides on neointimal hyperplasia in a rabbit vein graft model. J Mol Cell Cardiol 2006; 41: 431-440.
106. Shintani T, Sawa Y, Takahashi T, Matsumiya G, Matsuura N, Miyamoto Y, et al. Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model: A strategy to attenuate intimal hyperplasia. Ann Thorac Surg 2002; 74: 1132-1137; discussion 1137-1138.
107. Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: Therapeutic implications for cardiovascular diseases. PPAR Res 2008; 2008: 429123.
108. Turner NA, Hall KT, Ball SG, Porter KE. Selective gene silencing of either MMP-2 or MMP-9 inhibits invasion of human saphenous vein smooth muscle cells. Atherosclerosis 2007; 193: 36-43.
109. Eefting D, de Vries MR, Grimbergen JM, Karper JC, van Bockel JH, Quax PH. In vivo suppression of vein graft disease by non-viral, electroporation-mediated, gene transfer of tissue inhibitor of metalloproteinase-1 linked to the amino terminal fragment of urokinase (TIMP-1.ATF), a cell-surface directed matrix metallo-proteinase inhibitor. J Vasc Surg 2010; 51: 429-437.
110. Thomas AC, Newby AC. Effect of matrix metalloproteinase-9 knockout on vein graft remodelling in mice. J Vasc Res 2009; 47: 299-308.
111. Hu Y, Baker AH, Zou Y, Newby AC, Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 infuences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001; 21: 1275-1280.
112. Kallenbach K, Salcher R, Heim A, Karck M, Mignatti P, Haverich A. Inhibition of smooth muscle cell migration and neo-intima formation in vein grafts by overexpression of matrix metal-loproteinase-3. J Vasc Surg 2009; 49: 750-758.
113. Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, et al A new role for Nogo as a regulator of vascular remodeling. Nat Med 2004; 10: 382-388.
114. Kritz AB, Yu J, Wright PL, Wan S, George SJ, Halliday C, et al. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther 2008; 16: 1798-1804.
115. Haraguchi T, Okada K, Tabata Y, Maniwa Y, Hayashi Y, Okita Y. Controlled release of basic fbroblast growth factor from gelatin hydrogel sheet improves structural and physiological properties of vein graft in rat. Arterioscler Thromb Vasc Biol 2007; 27: 548-555.
116. Work LM, Reynolds PN, Baker AH. Improved gene delivery to human saphenous vein cells and tissue using a peptide-modifed adenoviral vector. Genet Vaccines Ther 2004; 2: 14.
117. Kilian EG, Eifert S, Beiras-Fernandez A, Daebritz S, Reichenspurner H, Reichart B. Adeno-associated virus-mediated gene transfer in a rabbit vein graft model. Circ J 2008; 72: 1700-1704.
118. Dishart KL, Denby L, George SJ, Nicklin SA, Yendluri S, Tuerk MJ, et al. Third-generation lentivirus vectors effciently transduce and phenotypically modify vascular cells: Implications for gene therapy. J Mol Cell Cardiol 2003; 35: 739-748.
119. King P, Royle JP. Autogenous vein grafting in atheromatous rabbits. Cardiovasc Res 1971; 6: 627-633.
120. Wyatt AP, Rothnie NG, Taylor GW. The vascularization of vein-grafts. Br J Surg 1964; 51: 378-381.
121. Albinsson S, Suarez Y, Skoura A, Offermanns S, Miano JM, et al. MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler Thromb Vasc Biol 2010 Apr 8 [Epub ahead of print].
122. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets 2010 Apr 26 [Epub ahead of print].
123. Weber C, Schober A, Zernecke A. MicroRNAs in arterial remodelling, infammation and atherosclerosis. Curr Drug Targets 2010 Apr 26 [Epub ahead of print].